Tharimmune (THAR) Financials

Tharimmune logo
$1.42 -0.22 (-13.41%)
As of 11/17/2026
Annual Income Statements for Tharimmune

Annual Income Statements for Tharimmune

This table shows Tharimmune's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-2.42 -2.21 -8.47 -9.32 -12 -36
Consolidated Net Income / (Loss)
-2.42 -2.21 -8.47 -9.32 -12 -36
Net Income / (Loss) Continuing Operations
-2.42 -2.21 -8.47 -9.32 -12 -36
Total Pre-Tax Income
-2.42 -2.21 -8.47 -9.32 -12 -42
Total Operating Income
-1.81 -3.21 -6.88 -9.46 -12 -20
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
1.81 3.21 6.88 9.46 12 20
Selling, General & Admin Expense
0.67 1.37 4.60 5.90 6.04 17
Research & Development Expense
1.14 1.84 2.28 3.56 6.39 3.07
Total Other Income / (Expense), net
-0.61 1.00 -1.59 0.14 0.24 -22
Interest Expense
0.25 0.83 1.59 0.02 0.01 0.03
Interest & Investment Income
- - 0.00 0.15 0.25 0.04
Other Income / (Expense), net
-0.36 1.83 - - - -22
Income Tax Expense
- - - - 0.00 -6.19
Basic Earnings per Share
($0.38) ($0.35) ($18.72) ($107.02) ($9.41) ($1.12)
Weighted Average Basic Shares Outstanding
6.35M 6.36M 452.69K 87.08K 1.30M 32.05M
Diluted Earnings per Share
($0.38) - ($18.72) ($107.02) ($9.41) ($1.12)
Weighted Average Diluted Shares Outstanding
6.35M 6.36M 452.69K 87.08K 1.30M 32.05M
Weighted Average Basic & Diluted Shares Outstanding
6.35M 6.36M 11.51M 11.74M 2.11M 56.66M

Quarterly Income Statements for Tharimmune

This table shows Tharimmune's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47 -19 -35
Consolidated Net Income / (Loss)
-2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47 -19 -35
Net Income / (Loss) Continuing Operations
-2.26 -2.33 -3.80 -3.82 -2.54 -1.43 -1.93 -29 -47 -18 -39
Total Pre-Tax Income
-2.26 -2.33 -3.80 -3.82 -2.54 -1.43 -1.93 -36 -52 -25 -54
Total Operating Income
-2.35 -2.37 -3.87 -3.85 -2.55 -1.43 -1.92 -14 -37 -1.20 0.34
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 1.50 3.05
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 1.50 3.05
Operating Revenue
- - - - - 0.00 0.00 - - 1.50 3.05
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
2.35 2.37 3.87 3.85 2.55 1.43 1.92 14 37 2.70 2.71
Selling, General & Admin Expense
1.32 1.37 1.58 1.76 1.95 1.30 1.82 12 37 2.70 2.71
Research & Development Expense
1.03 1.00 2.28 2.09 0.59 0.12 0.10 1.66 0.27 0.00 0.00
Total Other Income / (Expense), net
0.09 0.05 0.07 0.03 0.00 -0.00 -0.01 -22 -15 -23 -54
Interest Expense
0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00
Interest & Investment Income
0.10 0.05 0.07 0.03 0.01 0.00 0.00 0.02 0.32 0.31 0.38
Other Income / (Expense), net
- - - - - 0.00 0.00 - -15 -24 -55
Income Tax Expense
- - - - 0.00 0.00 0.00 - -4.22 -6.67 -15
Net Income / (Loss) Discontinued Operations
- - - - - -0.42 -0.18 - - -1.30 3.53
Basic Earnings per Share
($2.55) ($2.42) ($2.45) ($2.95) ($0.99) - ($0.34) ($0.92) ($0.23) - ($0.16)
Weighted Average Basic Shares Outstanding
885.68K 962.15K 1.55M 1.30M 2.57M 2.88M 6.24M 32.05M 207.71M 216.86M 218.44M
Diluted Earnings per Share
($2.55) ($2.42) ($2.45) ($2.95) ($0.99) - ($0.34) ($0.92) ($0.23) - ($0.16)
Weighted Average Diluted Shares Outstanding
885.68K 962.15K 1.55M 1.30M 2.57M 2.88M 6.24M 32.05M 207.71M 216.86M 218.44M
Weighted Average Basic & Diluted Shares Outstanding
11.79M 1.15M 1.49M 2.11M 2.66M 4.64M 35.04M 56.66M 69.80M 79.68M 81.64M

Annual Cash Flow Statements for Tharimmune

This table details how cash moves in and out of Tharimmune's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.15 -0.19 6.51 4.42 -7.38 13
Net Cash From Operating Activities
-1.08 -1.09 -6.56 -7.30 -11 -16
Net Cash From Continuing Operating Activities
-1.08 -1.09 -6.56 -7.30 -11 -16
Net Income / (Loss) Continuing Operations
-2.42 -2.21 -8.47 -9.32 -12 -36
Consolidated Net Income / (Loss)
-2.42 -2.21 -8.47 -9.32 -12 -36
Non-Cash Adjustments To Reconcile Net Income
0.89 -0.43 0.72 1.18 0.73 19
Changes in Operating Assets and Liabilities, net
0.31 0.88 -0.38 0.84 0.56 0.99
Net Cash From Investing Activities
0.00 0.00 0.00 0.00 0.00 -78
Net Cash From Continuing Investing Activities
0.00 0.00 0.00 0.00 0.00 -78
Other Investing Activities, net
- - - - 0.00 -78
Net Cash From Financing Activities
1.23 0.90 13 12 3.53 107
Net Cash From Continuing Financing Activities
1.23 0.90 13 12 3.53 107
Repayment of Debt
- 0.00 -0.14 - -0.66 -10
Issuance of Common Equity
- 0.00 14 12 4.19 116
Other Financing Activities, net
0.00 0.00 0.02 0.00 0.00 1.71
Cash Interest Paid
- - 0.02 0.02 0.01 0.03

Quarterly Cash Flow Statements for Tharimmune

This table details how cash moves in and out of Tharimmune's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-2.51 -0.53 -3.12 -1.21 -2.48 1.17 5.37 9.42 24 -9.61 -5.01
Net Cash From Operating Activities
-2.83 -2.18 -2.86 -3.03 -2.69 -1.14 -1.86 -10 -7.64 -2.24 -2.50
Net Cash From Continuing Operating Activities
-2.83 -2.18 -2.86 -3.03 -2.69 -1.15 -1.85 -10 -7.64 2.21 -2.49
Net Income / (Loss) Continuing Operations
-2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47 -16 -39
Consolidated Net Income / (Loss)
-2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47 -19 -35
Non-Cash Adjustments To Reconcile Net Income
0.17 0.15 0.19 0.21 0.22 0.56 0.63 17 43 13 39
Changes in Operating Assets and Liabilities, net
-0.74 -0.01 0.74 0.58 -0.37 0.14 -0.37 1.58 -3.34 2.90 -0.11
Net Cash From Discontinued Operating Activities
- - - - - - - - - - -0.01
Net Cash From Investing Activities
0.00 - - - 0.00 - - -78 -55 -5.76 -9.26
Net Cash From Continuing Investing Activities
0.00 - - - 0.00 - - -78 -55 -5.76 -9.26
Other Investing Activities, net
- - - - 0.00 - - - -55 -5.76 -9.26
Net Cash From Financing Activities
0.32 1.65 -0.26 1.82 0.21 2.31 7.22 97 87 4.29 0.86
Net Cash From Continuing Financing Activities
0.32 1.65 -0.26 1.82 0.21 2.31 7.22 97 87 4.29 0.86
Repayment of Debt
0.00 -0.32 -0.14 -0.20 -0.04 -0.29 -1.04 -8.83 -3.56 -0.07 -0.01
Issuance of Common Equity
- - - 2.10 0.00 - 8.32 105 90 4.27 0.87

Annual Balance Sheets for Tharimmune

This table presents Tharimmune's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
0.29 0.62 6.69 11 3.72 519
Total Current Assets
0.29 0.62 6.69 11 3.72 17
Cash & Equivalents
0.19 0.00 6.51 11 3.56 12
Note & Lease Receivable
- - - - - 0.00
Prepaid Expenses
0.10 0.07 0.18 0.01 0.05 0.20
Other Current Nonoperating Assets
- - - - - 5.18
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.00 0.00 0.00 0.00 0.00 502
Noncurrent Note & Lease Receivables
- - - - - 0.00
Other Noncurrent Operating Assets
- - - - 0.00 502
Total Liabilities & Shareholders' Equity
0.29 0.62 6.69 11 3.72 519
Total Liabilities
4.01 5.31 1.14 1.82 2.41 121
Total Current Liabilities
2.73 4.53 1.14 1.82 2.41 3.29
Accounts Payable
0.71 1.66 0.95 0.91 1.09 0.52
Accrued Expenses
0.05 0.32 - 0.91 1.32 0.51
Other Current Nonoperating Liabilities
0.07 0.18 0.19 - - 2.26
Total Noncurrent Liabilities
1.29 0.77 0.00 0.00 0.00 118
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - 118
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-3.72 -4.68 5.54 9.13 1.31 398
Total Preferred & Common Equity
-3.72 -4.68 5.54 9.13 1.31 398
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-3.72 -4.68 5.54 9.13 1.31 398
Common Stock
0.99 2.23 21 34 38 471
Retained Earnings
-4.70 -6.91 -15 -25 -37 -73
Treasury Stock
- 0.00 -0.07 -0.07 -0.07 -0.07

Quarterly Balance Sheets for Tharimmune

This table presents Tharimmune's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
3.17 8.89 8.26 5.25 1.66 2.53 7.70 585 565 514
Total Current Assets
3.17 8.89 8.26 5.25 1.66 2.53 7.70 43 41 29
Cash & Equivalents
2.69 8.43 7.90 4.77 1.08 2.24 7.61 42 37 27
Note & Lease Receivable
- - - - - - - - - 1.13
Prepaid Expenses
0.41 0.46 0.30 0.48 0.47 0.20 0.09 1.55 3.27 1.26
Other Current Nonoperating Assets
- - - - - - - - 0.70 0.00
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 542 523 485
Noncurrent Note & Lease Receivables
- - - - - - - - - 2.48
Other Noncurrent Operating Assets
- - - - - - - 542 523 482
Total Liabilities & Shareholders' Equity
3.17 8.89 8.26 5.25 1.66 2.53 7.70 585 565 514
Total Liabilities
1.41 1.84 1.56 2.23 2.48 2.16 1.54 115 110 93
Total Current Liabilities
1.41 1.84 1.56 2.23 2.48 2.16 1.54 1.14 2.63 1.54
Accounts Payable
1.14 0.99 0.78 0.78 0.84 0.77 0.66 0.40 0.92 0.05
Accrued Expenses
- - 0.58 1.37 1.12 1.06 0.69 0.74 0.98 1.49
Other Current Nonoperating Liabilities
0.19 0.53 - - - - - - 0.73 0.00
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 0.00 0.00 114 107 92
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - - - 114 107 92
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1.76 7.05 6.69 3.02 -0.81 0.37 6.15 470 455 421
Total Preferred & Common Equity
1.76 7.05 6.69 3.02 -0.81 0.37 6.15 470 455 421
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1.76 7.05 6.69 3.02 -0.81 0.37 6.15 470 455 421
Common Stock
24 34 36 36 39 42 50 590 594 595
Retained Earnings
-22 -27 -29 -33 -39 -41 -43 -120 -139 -174
Treasury Stock
-0.07 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07

Annual Metrics And Ratios for Tharimmune

This table displays calculated financial ratios and metrics derived from Tharimmune's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 0.00 11,529,861.00 17,511,839.00 1,486,037.00 35,044,812.00
DEI Adjusted Shares Outstanding
0.00 0.00 30,746.00 46,698.00 1,486,037.00 35,044,812.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -275.59 -199.56 -8.21 -1.02
Growth Metrics
- - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% 65.01% -649.57% -77.97% -31.50% -238.73%
EBIT Growth
0.00% 36.64% -400.37% -37.39% -31.50% -238.73%
NOPAT Growth
0.00% -77.40% -114.52% -37.39% -31.50% -61.71%
Net Income Growth
0.00% 8.72% -283.99% -9.98% -30.89% -194.45%
EPS Growth
0.00% 0.00% 0.00% -9.98% 91.21% 88.10%
Operating Cash Flow Growth
0.00% -0.72% -503.73% -11.32% -49.34% -47.94%
Free Cash Flow Firm Growth
0.00% 0.00% -238.31% 12.44% -47.66% -4,711.31%
Invested Capital Growth
0.00% -18.04% 66.88% -132.35% -24.82% 17,015.66%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% -54.60% -8.80% -11.84% -307.36%
EBIT Q/Q Growth
0.00% 0.00% -31.91% -8.80% -11.84% -307.36%
NOPAT Q/Q Growth
0.00% 0.00% -31.91% -8.80% -11.84% -94.47%
Net Income Q/Q Growth
0.00% 0.00% -99.19% -8.21% -12.41% -248.05%
EPS Q/Q Growth
0.00% 0.00% -99.19% -8.21% -34.24% 32.12%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -15.60% -7.71% -17.43% -84.95%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 3.97% -22.00% -5,059.02%
Invested Capital Q/Q Growth
0.00% 0.00% -61.50% -143.18% -28.18% 29,526.32%
Profitability Metrics
- - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 85.30%
Interest Burden Percent
111.36% 160.44% 123.12% 98.56% 98.10% 99.97%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
65.03% 52.52% -1,973.37% -127.01% -233.69% -17.99%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -104.29%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
65.03% 52.52% -1,973.37% -127.01% -233.69% -17.99%
Return on Equity Simple (ROE_SIMPLE)
65.03% 47.10% -152.84% -102.06% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.27 -2.25 -4.82 -6.62 -8.70 -14
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
66.50% -1.91% -183.74% -31.30% -48.21% -212.14%
Return On Investment Capital (ROIC_SIMPLE)
- - - -72.48% -665.60% -3.54%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-2.17 -1.38 -6.88 -9.46 -12 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-2.03 -0.71 -5.31 -9.46 -12 -42
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.81 0.04 2.31 0.27
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.81 0.04 2.31 0.27
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.23
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
-0.50 -0.46 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
-0.35 -0.17 0.00 0.00 0.00 0.00
Financial Leverage
-0.47 -0.48 -4.63 -1.18 -1.39 -0.05
Leverage Ratio
-0.08 -0.11 8.51 1.20 1.41 1.31
Compound Leverage Factor
-0.09 -0.18 10.48 1.18 1.38 1.31
Debt to Total Capital
-99.10% -85.95% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
-30.18% -55.27% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
-68.93% -30.68% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
199.10% 185.95% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.91 -3.06 0.00 0.00 0.00 0.00
Net Debt to EBITDA
-0.82 -3.05 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.64 -1.09 0.00 0.00 0.00 0.00
Debt to NOPAT
-1.46 -0.96 0.00 0.00 0.00 0.00
Net Debt to NOPAT
-1.31 -0.96 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-1.02 -0.34 0.00 0.00 0.00 0.00
Altman Z-Score
-54.29 -28.72 -3.27 -4.89 -23.74 0.09
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
0.11 0.14 5.84 6.03 1.54 5.29
Quick Ratio
0.07 0.00 5.69 6.02 1.47 5.18
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -1.89 -6.39 -5.59 -8.26 -397
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -2.27 -4.01 -338.75 -603.33 -14,013.73
Operating Cash Flow to Interest Expense
-4.37 -1.31 -4.12 -442.30 -796.70 -569.00
Operating Cash Flow Less CapEx to Interest Expense
-4.37 -1.31 -4.12 -442.30 -796.70 -569.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-1.99 -2.34 -0.78 -1.80 -2.25 381
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -0.36 1.57 -1.03 -0.45 383
Enterprise Value (EV)
17 17 -2.02 -11 -0.54 89
Market Capitalization
15 15 4.49 0.36 3.02 106
Book Value per Share
($0.59) ($0.74) $0.48 $0.52 $0.88 $11.35
Tangible Book Value per Share
($0.59) ($0.74) $0.48 $0.52 $0.88 $11.35
Total Capital
-1.87 -2.52 5.54 9.13 1.31 398
Total Debt
1.85 2.17 0.00 0.00 0.00 0.00
Total Long-Term Debt
1.29 0.77 0.00 0.00 0.00 0.00
Net Debt
1.66 2.16 -6.51 -11 -3.56 -17
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.06 -2.52 -0.97 -1.80 -2.25 -2.93
Debt-free Net Working Capital (DFNWC)
-1.87 -2.52 5.54 9.13 1.31 14
Net Working Capital (NWC)
-2.43 -3.91 5.54 9.13 1.31 14
Net Nonoperating Expense (NNE)
1.15 -0.04 3.66 2.70 3.49 22
Net Nonoperating Obligations (NNO)
1.73 2.34 -6.32 -11 -3.56 -17
Total Depreciation and Amortization (D&A)
0.15 0.67 1.57 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($131.25) ($281.25) ($107.10) ($9.41) ($1.12)
Adjusted Weighted Average Basic Shares Outstanding
0.00 30.31K 30.18K 87.03K 1.30M 32.05M
Adjusted Diluted Earnings per Share
$0.00 ($131.25) $0.00 ($107.10) ($9.41) ($1.12)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 30.31K 30.70K 87.03K 1.30M 32.05M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($131.25) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 16.95K 30.70K 782.65K 2.11M 56.66M
Normalized Net Operating Profit after Tax (NOPAT)
-1.27 -2.25 -4.82 -6.62 -8.70 -14
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-8.81 -1.65 -4.32 -572.87 -908.64 -1,485.85
NOPAT to Interest Expense
-5.13 -2.70 -3.03 -401.01 -636.05 -496.53
EBIT Less CapEx to Interest Expense
-8.81 -1.65 -4.32 -572.87 -908.64 -1,485.85
NOPAT Less CapEx to Interest Expense
-5.13 -2.70 -3.03 -401.01 -636.05 -496.53
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -8.12% -6.98% -5.57% 0.00% 0.00%

Quarterly Metrics And Ratios for Tharimmune

This table displays calculated financial ratios and metrics derived from Tharimmune's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
17,511,839.00 11,789,676.00 1,148,760.00 1,486,037.00 2,108,753.00 2,660,727.00 4,635,251.00 35,044,812.00 56,656,271.00 69,804,880.00 79,681,361.00
DEI Adjusted Shares Outstanding
46,698.00 785,978.00 1,148,760.00 1,486,037.00 2,108,753.00 2,660,727.00 4,635,251.00 35,044,812.00 56,656,271.00 69,804,880.00 79,681,361.00
DEI Earnings Per Adjusted Shares Outstanding
-48.31 -2.96 -3.30 -2.57 -1.21 -0.70 -0.45 -0.84 -0.84 -0.28 -0.44
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
13.52% -0.37% -109.51% -52.00% -8.49% 22.01% 45.84% -253.86% -1,937.23% -1,645.64% -2,732.41%
EBIT Growth
13.52% -0.37% -109.51% -52.00% -8.49% 22.01% 45.84% -253.86% -1,937.23% -1,645.64% -2,732.41%
NOPAT Growth
13.52% -0.37% -109.51% -52.00% -8.49% 22.01% 45.84% -253.86% -1,347.71% 15.85% 117.76%
Net Income Growth
16.08% 0.51% -108.55% -54.44% -12.66% 20.21% 44.63% -669.98% -1,762.66% -937.91% -1,568.93%
EPS Growth
16.08% 95.35% 93.78% 89.62% 61.18% 73.55% 86.12% 68.81% 76.77% 0.00% 52.94%
Operating Cash Flow Growth
18.46% -44.23% -215.07% -114.33% 4.82% 47.57% 35.22% -244.19% -183.94% -95.91% -34.83%
Free Cash Flow Firm Growth
64.06% 7.93% -64.11% -201.73% -10.33% 28.84% -14.00% -17,387.12% -44,845.60% -72,712.96% -21,780.38%
Invested Capital Growth
-573.87% -56.69% -136.80% -24.82% -90.41% -35.19% 26.32% 17,015.66% 26,550.21% 25,805.26% 30,520.62%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 103.98%
EBITDA Q/Q Growth
7.26% -1.11% -62.87% 0.47% 33.81% 27.31% -13.10% -550.31% -281.07% 51.93% -117.77%
EBIT Q/Q Growth
7.26% -1.11% -62.87% 0.47% 33.81% 27.31% -13.10% -550.31% -281.07% 51.93% -117.77%
NOPAT Q/Q Growth
7.26% -1.11% -62.87% 0.47% 33.81% 27.31% -13.10% -550.31% -170.80% 96.74% 128.33%
Net Income Q/Q Growth
8.80% -3.06% -63.26% -0.65% 33.47% 27.01% -13.30% -1,299.61% -60.94% 59.33% -82.18%
EPS Q/Q Growth
8.80% 5.10% -1.24% -20.41% 66.44% 35.35% 46.88% -170.59% 75.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-99.60% 22.86% -31.41% -5.93% 11.36% 57.51% -62.37% -462.84% 26.88% 70.68% -11.75%
Free Cash Flow Firm Q/Q Growth
-23.48% -33.48% -37.87% -32.79% 54.85% 13.91% -120.87% -20,269.12% -16.05% 7.80% 6.03%
Invested Capital Q/Q Growth
52.86% -41.34% -46.16% -28.18% 28.09% -0.36% 20.34% 29,526.32% 12.44% -2.47% -5.73%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,667.14% -1,779.86%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -80.37% 11.16%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,667.14% -1,779.86%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,287.21% -1,149.64%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 82.62% 91.82% 78.19% 65.04%
Interest Burden Percent
96.11% 97.96% 98.20% 99.30% 99.81% 100.22% 100.39% 261.52% 99.39% 98.75% 99.31%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.40% 0.18%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.52% 205.71%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.05% -16.56%
Return on Equity (ROE)
-173.40% -181.81% -454.53% -233.69% -400.44% -340.26% -225.01% -17.99% -34.42% -8.46% -16.38%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -104.29% -109.27% -109.47% -109.56%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.79% -31.03%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.79% -20.04%
Return on Common Equity (ROCE)
-173.40% -181.81% -454.53% -233.69% -400.44% -340.26% -225.01% -17.99% -34.42% -8.46% -16.38%
Return on Equity Simple (ROE_SIMPLE)
-126.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.64 -1.66 -2.71 -2.69 -1.78 -1.30 -1.47 -9.53 -26 -0.84 0.24
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -56.26% 7.81%
Net Nonoperating Expense Percent (NNEP)
-10.92% -11.31% -29.97% -15.56% -17.44% -11.31% -10.41% -193.15% -101.73% -93.92% -205.53%
Return On Investment Capital (ROIC_SIMPLE)
-23.31% -24.82% -89.67% -205.96% 328.17% -209.99% -23.20% -2.40% -5.49% -0.19% 0.06%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 180.37% 88.84%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 180.37% 88.84%
Earnings before Interest and Taxes (EBIT)
-2.35 -2.37 -3.87 -3.85 -2.55 -1.85 -2.09 -14 -52 -25 -54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-2.35 -2.37 -3.87 -3.85 -2.55 -1.85 -2.09 -14 -52 -25 -54
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.04 0.41 0.94 2.31 0.00 14.05 2.14 0.27 0.39 0.43 0.45
Price to Tangible Book Value (P/TBV)
0.04 0.41 0.94 2.31 0.00 14.05 2.14 0.27 0.39 0.43 0.45
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 131.60 41.62
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.34 0.38 0.41
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 106.70 35.70
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 -0.33 0.68 0.03 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.10 -1.20 -1.52 -1.39 -1.40 -1.40 -1.33 -0.05 -0.09 -0.09 -0.08
Leverage Ratio
1.33 1.32 1.76 1.41 1.69 1.53 1.41 1.31 1.25 1.25 1.22
Compound Leverage Factor
1.28 1.29 1.73 1.40 1.69 1.53 1.42 3.43 1.24 1.23 1.21
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% -49.97% 40.47% 2.55% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% -49.97% 40.47% 2.55% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 149.97% 59.53% 97.45% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 -0.02 -0.02 -0.02 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.06 0.16 0.72 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 -0.03 -0.03 -0.02 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.09 0.24 1.03 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-4.07 -3.88 -9.79 -16.12 -38.19 -23.66 -2.72 0.28 0.47 0.67 0.47
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.84 5.28 2.35 1.54 0.67 1.17 4.98 5.29 37.75 15.70 19.05
Quick Ratio
4.59 5.05 2.14 1.47 0.43 1.04 4.93 5.18 36.39 14.18 18.23
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-0.92 -1.23 -1.69 -2.25 -1.01 -0.87 -1.93 -393 -456 -420 -395
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-195.52 -235.11 -562.00 -2,962.42 -119.69 -141.67 -199.81 -96,599.04 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-601.10 -417.73 -951.76 -4,002.17 -317.44 -185.45 -192.29 -2,568.66 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-601.10 -417.73 -951.76 -4,002.17 -317.44 -185.45 -192.29 -2,568.66 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.85 -1.20 -1.76 -2.25 -1.62 -1.62 -1.29 381 428 418 394
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02
Increase / (Decrease) in Invested Capital
-0.72 -0.43 -1.01 -0.45 -0.77 -0.42 0.46 383 430 419 395
Enterprise Value (EV)
-8.13 -5.12 -1.93 -0.54 2.06 3.17 5.71 89 144 160 162
Market Capitalization
0.30 2.77 2.85 3.02 2.87 5.16 13 106 185 197 189
Book Value per Share
$7.96 $0.57 $2.63 $0.88 ($0.39) $0.14 $1.33 $11.35 $13.41 $6.52 $5.28
Tangible Book Value per Share
$7.96 $0.57 $2.63 $0.88 ($0.39) $0.14 $1.33 $11.35 $13.41 $6.52 $5.28
Total Capital
7.05 6.69 3.02 1.31 -0.54 0.62 6.32 398 470 455 421
Total Debt
0.00 0.00 0.00 0.00 0.27 0.25 0.16 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-8.43 -7.90 -4.77 -3.56 -0.80 -1.99 -7.45 -17 -42 -37 -27
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.38 -1.20 -1.76 -2.25 -1.62 -1.62 -1.29 -2.93 0.41 1.35 0.85
Debt-free Net Working Capital (DFNWC)
7.05 6.69 3.02 1.31 -0.54 0.62 6.32 14 42 39 28
Net Working Capital (NWC)
7.05 6.69 3.02 1.31 -0.81 0.37 6.15 14 42 39 28
Net Nonoperating Expense (NNE)
0.61 0.66 1.09 1.13 0.76 0.56 0.64 20 22 18 35
Net Nonoperating Obligations (NNO)
-7.90 -7.90 -4.77 -3.56 -0.80 -1.99 -7.45 -17 -42 -37 -27
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 90.19% 18.61%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,579.83% 610.58%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,579.83% 610.58%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($2.85) ($2.42) ($2.45) ($2.95) ($0.99) ($0.64) ($0.34) ($0.92) ($0.23) $0.00 ($0.16)
Adjusted Weighted Average Basic Shares Outstanding
783.85K 962.15K 1.55M 1.30M 2.57M 2.88M 6.24M 32.05M 207.71M 216.86M 218.44M
Adjusted Diluted Earnings per Share
($2.85) ($2.42) ($2.45) ($2.95) ($0.99) ($0.64) ($0.34) ($0.92) ($0.23) $0.00 ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding
783.85K 962.15K 1.55M 1.30M 2.57M 2.88M 6.24M 32.05M 207.71M 216.86M 218.44M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($2.95) $0.00 $0.00 $0.00 ($0.92) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
785.98K 1.15M 1.49M 2.11M 2.66M 4.64M 35.04M 56.66M 69.80M 79.68M 81.64M
Normalized Net Operating Profit after Tax (NOPAT)
-1.64 -1.66 -2.71 -2.69 -1.78 -1.30 -1.47 -9.53 -26 -0.84 0.24
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -56.26% 7.81%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,646.30% -1,767.51%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-499.43 -454.95 -1,284.67 -5,075.81 -300.63 -300.46 -217.00 -3,349.24 0.00 0.00 0.00
NOPAT to Interest Expense
-349.60 -318.46 -899.27 -3,553.07 -210.44 -210.32 -151.90 -2,344.47 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-499.43 -454.95 -1,284.67 -5,075.81 -300.63 -300.46 -217.00 -3,349.24 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-349.60 -318.46 -899.27 -3,553.07 -210.44 -210.32 -151.90 -2,344.47 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Important data note: The supplied statements identify the company as Canton Strategic Holdings, Inc. (CNTN) and, in earlier periods, Hillstream BioPharma Inc., rather than Tharimmune (NASDAQ: THAR). The analysis below therefore reflects the financial data provided, not verified Tharimmune statements. The dataset also contains restated and calculated periods, so historical comparisons should be treated cautiously.

The company’s financial profile changed significantly between late 2023 and the second quarter of 2026. Revenue was zero in nearly every reported quarter, but Q2 2026 recorded $1.5 million of revenue. Despite that improvement, the company remained unprofitable, reporting a consolidated net loss of $19.3 million in Q2 2026 after losses of $47.3 million in Q1 and $29.4 million in Q4 2025.

  • Revenue appeared for the first time in the provided recent periods. Q2 2026 operating revenue totaled $1.5 million, compared with no revenue in Q1 2026 and the prior reported quarters. This may indicate the beginning of commercialization or another source of operating activity, although one quarter is not enough to establish a trend.
  • Operating expenses declined sharply sequentially. Total operating expenses fell to $2.7 million in Q2 2026 from $36.9 million in Q1 2026 and $13.6 million in Q4 2025. Selling, general and administrative expense was the primary driver of the Q1 spike, falling from $36.6 million to $2.7 million in Q2.
  • Operating cash flow improved in Q2. Net cash used in operating activities narrowed to $2.2 million from $7.6 million in Q1 2026 and $10.4 million in Q4 2025. This improvement reflects the lower operating expense burden and positive changes in operating assets and liabilities during Q2.
  • Liquidity remained substantial. Cash and equivalents totaled $37.2 million at June 30, 2026, while current liabilities were $2.6 million. On the reported balance sheet, this represents a current ratio of approximately 15.7, providing a meaningful near-term liquidity cushion.
  • Debt repayment reduced financing obligations. The company repaid approximately $3.6 million of debt in Q1 2026 and an additional $69,000 in Q2. Total reported liabilities declined from $114.9 million at March 31 to $109.7 million at June 30.
  • The Q2 net loss was heavily affected by non-operating items. Other expense reached $23.7 million, producing a total pretax loss of $24.6 million despite positive revenue and lower operating expenses. Investors should determine whether this charge is recurring, non-cash, or related to accounting revaluations before judging underlying operating performance.
  • Balance-sheet assets were dominated by noncurrent assets. Other noncurrent operating assets totaled $523.4 million, or most of the company’s $564.6 million in total assets. Because the data does not explain the composition or liquidity of these assets, their valuation and recoverability are important areas for further review.
  • The company continued to generate substantial net losses. Losses have persisted throughout the supplied periods, including $2.5 million in Q1 2024, $3.8 million in Q4 2024, $29.4 million in Q4 2025, $47.3 million in Q1 2026 and $19.3 million in Q2 2026. Retained earnings reached a deficit of $139.4 million by June 30, 2026.
  • Cash flow remained negative from operations. The company has reported negative operating cash flow in every supplied cash-flow period. Although Q2 2026’s $2.2 million operating cash outflow was an improvement, continued cash burn means liquidity may depend on future revenue growth, asset monetization, or additional financing.
  • Funding has relied heavily on equity issuance. The company raised $90.4 million through common equity issuance in Q1 2026 and another $4.3 million in Q2, following $104.6 million in Q4 2025. Weighted average basic shares increased from 207.7 million in Q1 to 216.9 million in Q2, highlighting ongoing dilution risk for existing shareholders.

Overall, the statements show possible early progress in revenue generation, expense control and operating cash burn, but the investment case remains high risk. Persistent losses, negative operating cash flow, large non-operating charges and repeated equity issuance outweigh the improved liquidity position until the company demonstrates recurring revenue and a path toward sustainable profitability.

11/18/26 11:52 PM ETAI Generated. May Contain Errors.

Tharimmune Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tharimmune's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Tharimmune's net income appears to be on a downward trend, with a most recent value of -$35.92 million in 2025, falling from -$2.42 million in 2020. The previous period was -$12.20 million in 2024. View Tharimmune's forecast to see where analysts expect Tharimmune to go next.

Tharimmune's total operating income in 2025 was -$20.11 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $20.11 million

Over the last 5 years, Tharimmune's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Tharimmune's cash and equivalents has ranged from $1.08 million in Q1 2025 to $41.53 million in Q1 2026, and is currently $26.92 million as of their latest financial filing in Q3 2026.

Tharimmune had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2020.

Over the last 5 years, Tharimmune's book value per share changed from -0.59 in 2020 to 11.35 in 2025.



Financial statements for NASDAQ:THAR last updated on 11/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners